1-[2-(dimetoxyphosphoryl)acetyl]-1-hexanoylcyclopropane | 1203929-77-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: 1-[2-(dimetoxyphosphoryl)acetyl]-1-hexanoylcyclopropane
• 英文别名: 1-[2-(dimethoxy-phosphoryl)-acetyl]-1-hexanoyl-cyclopropane；1-[2-(Dimetoxy-phosphoryl)-acetyl]-1-hexanoyl-cyclopropane；1-[1-(2-dimethoxyphosphorylacetyl)cyclopropyl]hexan-1-one
• CAS: 1203929-77-4
• 化学式: C₁₃H₂₃O₅P
• 分子量: 290.296
• InChiKey: SEROCYLPIXATBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[2-(dimetoxyphosphoryl)acetyl]-1-hexanoylcyclopropane 、 甲基三苯基溴化膦 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 以68%的产率得到1-[2-(dimetoxyphosphoryl)acetyl]-1-(1-methylenehexyl)cyclopropane
  参考文献：
  名称：

  2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs

  摘要：

  本发明公开了2-亚甲基-(22E)-25-(1-亚甲基-己基)-26,27-环-22-去氢-19-去甲基维生素D类似物，具体为2-亚甲基-(22E)-25-(1-亚甲基-己基)-26,27-环-22-去氢-19-去甲基-1α,24(R)-二羟基维生素D3，以及其药用用途。该化合物表现出相对较高的转录活性，以及在抑制未分化细胞增殖并诱导其分化为单核细胞方面的显著活性，从而证明其用作抗癌剂以及治疗银屑病等皮肤疾病以及皮肤条件，如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足。与天然激素1α,25-二羟基维生素D3相比，该化合物在体内对骨钙动员和肠钙转运活性的活性较低，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及肾性骨病。该化合物还可用于治疗或预防肥胖症。

  公开号：

  US20100009943A1
• 作为产物：
  描述：

  2-庚酮 在 三乙基硅基三氟甲磺酸酯 、 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 反应 48.5h， 生成 1-[2-(dimetoxyphosphoryl)acetyl]-1-hexanoylcyclopropane
  参考文献：
  名称：

  2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs

  摘要：

  这项发明揭示了2-亚甲基-(22E)-25-己酰基-24-酮-26,27-环-22-脱氢-19-去甲维生素D类似物，具体包括2-亚甲基-(22E)-25-己酰基-24-酮-26,27-环-22-脱氢-19-去甲-1α-羟基维生素D3，以及其药用用途。该化合物表现出相对较高的转录活性，以及在阻止未分化细胞增殖并诱导它们分化为单核细胞方面表现出显著活性，从而证明其用作抗癌剂以及治疗银屑病等皮肤疾病以及皮肤状况，如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足。该化合物在体内对骨钙动员的活性也较低，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及肾性骨病。该化合物还可用于治疗或预防肥胖。

  公开号：

  US20130005686A1

文献信息

• 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
  申请人：Wisconsin Alumni Research Foundation

  公开号：US07713953B2

  公开（公告）日：2010-05-11

  This invention discloses 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-1α,24(R)-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and intestinal calcium transport activity compared to the native hormone 1α,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明揭示了2-亚甲基-(22E)-25-(1-亚甲基-己基)-26,27-环-22-去氢-19-去氢维生素D类似物，特别是2-亚甲基-(22E)-25-(1-亚甲基-己基)-26,27-环-22-去氢-19-去氢-1α,24(R)-二羟基维生素D3，以及其药物用途。该化合物表现出相对较高的转录活性，以及在阻止未分化细胞增殖和诱导它们分化为单核细胞方面表现出显著活性，因此可用作抗癌剂和治疗牛皮癣等皮肤疾病以及皮肤状况，如皱纹、松弛的皮肤、干燥的皮肤和不足的皮脂分泌。与原生激素1α,25-二羟基维生素D3相比，该化合物在体内对骨钙动员和肠钙转运活性的活性较低，因此可用于治疗人类的自身免疫性疾病或炎症性疾病以及肾性骨营养不良。该化合物还可用于治疗或预防肥胖症。
• 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
  申请人：DeLuca Hector F.

  公开号：US10479764B2

  公开（公告）日：2019-11-19

  This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1α-hydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows low activity in vivo on bone calcium mobilization, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  本发明公开了 2-亚甲基-(22E)-25-己酰基-24-氧代-26,27-环-22-脱氢-19-去甲-1α-羟基维生素 D 类似物，特别是 2-亚甲基-(22E)-25-己酰基-24-氧代-26,27-环-22-脱氢-19-去甲-1α-羟基维生素 D3 及其药物用途。这种化合物具有相对较高的转录活性，在抑制未分化细胞的增殖和诱导其向单核细胞分化方面具有明显的活性，因此证明可用作抗癌剂和治疗牛皮癣等皮肤病以及皱纹、皮肤松弛、皮肤干燥和皮脂分泌不足等皮肤病。该化合物在体内对骨钙动员的活性也较低，因此可用于治疗人类自身免疫性疾病或炎症性疾病以及肾性骨营养不良症。这种化合物还可用于治疗或预防肥胖症。
• US7713953B2
  申请人：——

  公开号：US7713953B2

  公开（公告）日：2010-05-11
• [EN] 2-METHYLENE-(22E)-25-(1-METHYLENE-HEXYL)-26,27-CYCLO-22-DEHYDRO-19-NOR-VITAMIN D ANALOGS<br/>[FR] ANALOGUES DE LA 2-MÉTHYLÈNE-(22E)-25-(1-MÉTHYLÈNE-HEXYL)-26,27-CYCLO-22-DÉSHYDRO-19-NOR-VITAMINE D
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2010006129A2

  公开（公告）日：2010-01-14

  This invention discloses 2-methylene-(22E)-25-(l-methylene-hexyl)-26,27- cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25- ( 1 -methylene-hexyl)-26,27-cyclo-22-dehydro- 19-nor- 1 α,24(R)-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti¬ cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and intestinal calcium transport activity compared to the native hormone lα,25- dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
• 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs
  申请人：DeLuca Hector F.

  公开号：US20130005686A1

  公开（公告）日：2013-01-03

  This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1α-hydroxyvitamin D 3 , and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows low activity in vivo on bone calcium mobilization, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

  这项发明揭示了2-亚甲基-(22E)-25-己酰基-24-酮-26,27-环-22-脱氢-19-去甲维生素D类似物，具体包括2-亚甲基-(22E)-25-己酰基-24-酮-26,27-环-22-脱氢-19-去甲-1α-羟基维生素D3，以及其药用用途。该化合物表现出相对较高的转录活性，以及在阻止未分化细胞增殖并诱导它们分化为单核细胞方面表现出显著活性，从而证明其用作抗癌剂以及治疗银屑病等皮肤疾病以及皮肤状况，如皱纹、松弛皮肤、干燥皮肤和皮脂分泌不足。该化合物在体内对骨钙动员的活性也较低，因此可用于治疗人类的自身免疫性疾病或炎症性疾病，以及肾性骨病。该化合物还可用于治疗或预防肥胖。